Data and tools

Substance misuse treatment for young people: This data looks at the alcohol and drug treatment data for under-18s from PHE’s National Drug Treatment Monitoring System (NDTMS) from April 2019 to March 2020. The statistics show that 2/3 of children in treatment were male with the median age being 15. There was a 3% reduction in the number of young people in treatment from the year before, with cannabis remaining the most common substance (89%) that young people come to treatment for. Read the accompanying report here.

Reports and briefings

Brexit and child health - summary of agreements: RCPCH has summarised and reviewed the agreements made in the UK-EU deal that will have an impact on child health with medicine supply, workforce, data and research and so on.

Research

Population vs Individual Prediction of Poor Health From Results of Adverse Childhood Experiences Screening: While adverse childhood experiences (ACEs) are well established risk factors for health problems in a population, this study aims to identify whether ACEs can accurately predict individuals who go on to develop health problems. The study used 2 birth cohorts to conduct the statistical analysis: The Environmental Risk (E-Risk) Longitudinal Twin Study and the Dunedin Multidisciplinary Health and Development Study. ACEs were measured prospectively, but also measured retrospectively in the Dunedin cohort. The findings showed that while ACEs scores can forecast mean group differences in the health, the authors showed that they have poor accuracy is predicting an individual’s risk of developing health problem later on. Therefore, targeting interventions that are based on ACE screening are not likely to be effective in preventing poor health outcomes.

Sign up now

King's Health Partner's "Meet the expert": hosted in collaboration with the European University Hospital Alliance, the global clinical seminar series takes place on Tuesdays at 1pm GMT.
Ocular gene therapy - a vision for the future, 23 February 2021: Professor Robin Ali will give a broad overview of the field, current clinical trials and potential for clinical impact.
ESC-derived progenitors, 2 March 2021: Professor Philippe Menasché will provide a survey of the trials on cardiac cell repair for heart failure and the discuss the current  trends for improving outcomes.
Treating sickle cell disease - beyond Hydroxyurea, 9 March 2021: Professor Swee Lay Thain will discuss genetic therapy, recent FDA approved drugs for managing sickle cell plus new developments in the drug pipeline for sickle cell disease.

Cron Job Starts